Novel therapies for asthma - Advances and problems

Research output: Contribution to journalLiterature review

28 Citations (Scopus)

Abstract

It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. While corticosteroids remain the most important anti-inflammatory treatment for asthma they are rather non-specific in their actions. Their use also raises concerns over side effects and compliance issues, particularly in children and adolescents. There is therefore much effort being made to develop novel more specific and safer therapy for asthma. Efforts are being made to improve existing drugs together with the use of combination therapy with anti-histamines and leukotriene antagonists. An important area for potential advances in glucocorticoid (GC) development include the elucidation of the crystal structure of the GC receptor ligand-binding domain that may provide vital information in dissociating the anti-inflammatory effects of GCs from unwanted side-effects. Other areas include the development of humanised monoclonal antibodies for asthma therapy including those against IgE, IL-4 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for inflammatory cell accumulation in the asthmatic lung. The potential for immunotherapy using T cell peptide epitopes or DNA-based vaccines and the use of anti-inflammatory cytokines such as IL-10 or IFN-gamma are discussed. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. Novel strategies include elucidation of the intracellular pathways controlling granulocyte apoptosis and the receptor mediated events employed by macrophages and bronchial epithelial cells in the recognition and removal of apoptotic cellular corpses. This paper will provide an overview of both the potential and shortcomings of these diverse approaches to drug development for asthma.

Original languageEnglish
Pages (from-to)3027-3038
Number of pages12
JournalCurrent Pharmaceutical Design
Volume11
Publication statusPublished - 2005

Keywords

  • asthma
  • corticosteroids
  • inflammation
  • T cells
  • immunotherapy
  • cell accumulation
  • eosinophils
  • apoptosis
  • phagocytosis
  • COLONY-STIMULATING FACTOR
  • ENGULF APOPTOTIC EOSINOPHILS
  • MESSENGER-RNA EXPRESSION
  • PLACEBO-CONTROLLED TRIAL
  • AIRWAY EPITHELIAL-CELLS
  • CHEMOKINE RECEPTOR CCR3
  • KAPPA-B ACTIVATION
  • ANTI-IGE ANTIBODY
  • ALLERGIC-ASTHMA
  • MONOCLONAL-ANTIBODY

Cite this

Novel therapies for asthma - Advances and problems. / Walsh, G M .

In: Current Pharmaceutical Design, Vol. 11, 2005, p. 3027-3038.

Research output: Contribution to journalLiterature review

@article{1a960f6c2ddc4450b8c6b62fc5057ff3,
title = "Novel therapies for asthma - Advances and problems",
abstract = "It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. While corticosteroids remain the most important anti-inflammatory treatment for asthma they are rather non-specific in their actions. Their use also raises concerns over side effects and compliance issues, particularly in children and adolescents. There is therefore much effort being made to develop novel more specific and safer therapy for asthma. Efforts are being made to improve existing drugs together with the use of combination therapy with anti-histamines and leukotriene antagonists. An important area for potential advances in glucocorticoid (GC) development include the elucidation of the crystal structure of the GC receptor ligand-binding domain that may provide vital information in dissociating the anti-inflammatory effects of GCs from unwanted side-effects. Other areas include the development of humanised monoclonal antibodies for asthma therapy including those against IgE, IL-4 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for inflammatory cell accumulation in the asthmatic lung. The potential for immunotherapy using T cell peptide epitopes or DNA-based vaccines and the use of anti-inflammatory cytokines such as IL-10 or IFN-gamma are discussed. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. Novel strategies include elucidation of the intracellular pathways controlling granulocyte apoptosis and the receptor mediated events employed by macrophages and bronchial epithelial cells in the recognition and removal of apoptotic cellular corpses. This paper will provide an overview of both the potential and shortcomings of these diverse approaches to drug development for asthma.",
keywords = "asthma, corticosteroids, inflammation, T cells, immunotherapy, cell accumulation, eosinophils, apoptosis, phagocytosis, COLONY-STIMULATING FACTOR, ENGULF APOPTOTIC EOSINOPHILS, MESSENGER-RNA EXPRESSION, PLACEBO-CONTROLLED TRIAL, AIRWAY EPITHELIAL-CELLS, CHEMOKINE RECEPTOR CCR3, KAPPA-B ACTIVATION, ANTI-IGE ANTIBODY, ALLERGIC-ASTHMA, MONOCLONAL-ANTIBODY",
author = "Walsh, {G M}",
year = "2005",
language = "English",
volume = "11",
pages = "3027--3038",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Novel therapies for asthma - Advances and problems

AU - Walsh, G M

PY - 2005

Y1 - 2005

N2 - It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. While corticosteroids remain the most important anti-inflammatory treatment for asthma they are rather non-specific in their actions. Their use also raises concerns over side effects and compliance issues, particularly in children and adolescents. There is therefore much effort being made to develop novel more specific and safer therapy for asthma. Efforts are being made to improve existing drugs together with the use of combination therapy with anti-histamines and leukotriene antagonists. An important area for potential advances in glucocorticoid (GC) development include the elucidation of the crystal structure of the GC receptor ligand-binding domain that may provide vital information in dissociating the anti-inflammatory effects of GCs from unwanted side-effects. Other areas include the development of humanised monoclonal antibodies for asthma therapy including those against IgE, IL-4 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for inflammatory cell accumulation in the asthmatic lung. The potential for immunotherapy using T cell peptide epitopes or DNA-based vaccines and the use of anti-inflammatory cytokines such as IL-10 or IFN-gamma are discussed. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. Novel strategies include elucidation of the intracellular pathways controlling granulocyte apoptosis and the receptor mediated events employed by macrophages and bronchial epithelial cells in the recognition and removal of apoptotic cellular corpses. This paper will provide an overview of both the potential and shortcomings of these diverse approaches to drug development for asthma.

AB - It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. While corticosteroids remain the most important anti-inflammatory treatment for asthma they are rather non-specific in their actions. Their use also raises concerns over side effects and compliance issues, particularly in children and adolescents. There is therefore much effort being made to develop novel more specific and safer therapy for asthma. Efforts are being made to improve existing drugs together with the use of combination therapy with anti-histamines and leukotriene antagonists. An important area for potential advances in glucocorticoid (GC) development include the elucidation of the crystal structure of the GC receptor ligand-binding domain that may provide vital information in dissociating the anti-inflammatory effects of GCs from unwanted side-effects. Other areas include the development of humanised monoclonal antibodies for asthma therapy including those against IgE, IL-4 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for inflammatory cell accumulation in the asthmatic lung. The potential for immunotherapy using T cell peptide epitopes or DNA-based vaccines and the use of anti-inflammatory cytokines such as IL-10 or IFN-gamma are discussed. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. Novel strategies include elucidation of the intracellular pathways controlling granulocyte apoptosis and the receptor mediated events employed by macrophages and bronchial epithelial cells in the recognition and removal of apoptotic cellular corpses. This paper will provide an overview of both the potential and shortcomings of these diverse approaches to drug development for asthma.

KW - asthma

KW - corticosteroids

KW - inflammation

KW - T cells

KW - immunotherapy

KW - cell accumulation

KW - eosinophils

KW - apoptosis

KW - phagocytosis

KW - COLONY-STIMULATING FACTOR

KW - ENGULF APOPTOTIC EOSINOPHILS

KW - MESSENGER-RNA EXPRESSION

KW - PLACEBO-CONTROLLED TRIAL

KW - AIRWAY EPITHELIAL-CELLS

KW - CHEMOKINE RECEPTOR CCR3

KW - KAPPA-B ACTIVATION

KW - ANTI-IGE ANTIBODY

KW - ALLERGIC-ASTHMA

KW - MONOCLONAL-ANTIBODY

M3 - Literature review

VL - 11

SP - 3027

EP - 3038

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

ER -